Understanding cepmox and its role in bacterial infection treatment
Bacterial infections represent one of the most common reasons for seeking medical care worldwide, affecting every organ system and ranging in severity from mild, self-limited conditions to life-threatening systemic illnesses. The discovery and development of antibiotics is one of the most transformative achievements in the history of medicine, dramatically reducing morbidity and mortality from infectious diseases that once claimed millions of lives. Among the antibiotics that have become household names, Amoxicillin, the active ingredient in Cepmox, has a position of particular prominence as one of the most widely prescribed antibiotics on the global market. Its broad spectrum of activity, favorable safety profile, excellent oral absorption, and availability in multiple convenient formulations have made it a first-line treatment for many common bacterial infections.
Cepmox belongs to the beta-lactam class of antibiotics, specifically the aminopenicillin subgroup within the larger penicillin family. Beta-lactam antibiotics derive their name from the beta-lactam ring that is essential to their antibacterial activity, a four-membered cyclic amide that structurally mimics the D-alanyl-D-alanine terminus of peptidoglycan precursors. This structural mimicry is the key to the mechanism of action of these antibiotics. The beta-lactam ring binds covalently to and irreversibly inactivates penicillin-binding proteins, which are enzymes essential for the synthesis and maintenance of the bacterial cell wall. By inhibiting these enzymes, Amoxicillin disrupts the cross-linking of peptidoglycan strands that provides structural integrity to the bacterial cell wall, ultimately leading to cell lysis and death through osmotic rupture. This bactericidal mechanism is particularly effective against actively growing and dividing bacteria that are continuously synthesizing new cell wall material.
The spectrum of activity of Amoxicillin encompasses many clinically important bacterial pathogens, including many gram-positive organisms such as Streptococcus species, Enterococcus faecalis, and Listeria monocytogenes, and a significant number of gram-negative organisms including Haemophilus influenzae, Escherichia coli, and Proteus mirabilis. The addition of the amino group to the penicillin nucleus, which distinguishes Amoxicillin from its parent compound ampicillin, enhances oral absorption and results in higher and more reliable serum concentrations following oral administration. This pharmacokinetic advantage, combined with the medication’s tolerability and established efficacy, has made Cepmox a foundation of antibiotic therapy in both outpatient and inpatient settings across the world.
Common infections treated with cepmox
The clinical applications of Cepmox span many infectious conditions affecting multiple organ systems, reflecting medication’s broad antibacterial spectrum and excellent tissue penetration. Respiratory tract infections are among the most frequent indications for Amoxicillin therapy, including acute otitis media in children, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia caused by susceptible organisms. In acute otitis media, Amoxicillin is the recommended first-line antibiotic for most children, providing coverage against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, which together account for the majority of bacterial ear infections in the pediatric population.
Streptococcal pharyngitis, commonly known as strep throat, is another important indication for Amoxicillin, although penicillin V is often recommended as the preferred agent. Amoxicillin is a reasonable alternative, particularly in children for whom the palatability of the liquid formulation may improve adherence compared to penicillin suspensions. The treatment of streptococcal pharyngitis is important not only for symptomatic relief and for the prevention of suppurative complications including peritonsillar abscess and the nonsuppurative complication of acute rheumatic fever, which can cause permanent damage to the heart valves. A complete course of antibiotic therapy is essential to eradicate the organism and prevent these sequelae, and patients should be counseled about the importance of completing the full prescribed course even if symptoms resolve earlier.
Urinary tract infections caused by susceptible organisms represent another common indication for Amoxicillin. The medication achieves high concentrations in the urine following oral administration, making it effective against many urinary pathogens. However, the increasing prevalence of resistance among Escherichia coli and other common uropathogens has limited the empiric use of Amoxicillin for urinary tract infections, and culture and susceptibility testing are recommended whenever possible to guide therapy. In uncomplicated cystitis, alternative agents with lower resistance rates are often preferred for empiric treatment while awaiting culture results.
Dental infections, including periapical abscesses, periodontal infections, and post-procedural infections, are frequently treated with Amoxicillin due to its activity against the oral anaerobes and streptococci that predominate in odontogenic infections. The medication is also used for antibiotic prophylaxis before dental procedures in patients at high risk of infective endocarditis, an infection of the heart valves that can result from the transient bacteremia that occurs during dental manipulation. While the indications for antibiotic prophylaxis have been narrowed in recent guidelines, it remains recommended for patients with prosthetic heart valves, previous infective endocarditis, certain congenital heart conditions, and cardiac transplant recipients with valvulopathy.
Helicobacter pylori eradication is another important indication for Amoxicillin, used as part of combination therapy with a proton pump inhibitor and one or two additional antibiotics, most commonly clarithromycin or metronidazole. H. Pylori infection is the primary cause of peptic ulcer disease and is a major risk factor for gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue lymphoma. Eradication of the organism heals ulcers, prevents recurrence, and reduces the long-term risk of gastric malignancy. The inclusion of Amoxicillin in H. Pylori treatment regimens reflects its activity against the organism and the relatively low rates of resistance observed compared to other antibiotics used for this indication.
Pharmacokinetic properties and dosing
The pharmacokinetic characteristics of Cepmox contribute to its clinical utility and have informed the development of dosing regimens for different indications and patient populations. Following oral administration, Amoxicillin is rapidly and well absorbed from the gastrointestinal tract, with bioavailability of approximately seventy to ninety percent, which is higher than that of ampicillin and largely unaffected by food intake. Peak serum concentrations are typically achieved within one to two hours of dosing, and the medication distributes widely into tissues and body fluids, including the middle ear, sinuses, respiratory tract, urine, and bile. Therapeutic concentrations are achieved in most tissues relevant to the treatment of common infections, although penetration into the cerebrospinal fluid is limited except when the meninges are inflamed.
The elimination of Amoxicillin occurs primarily through renal excretion, with the majority of the administered dose recovered unchanged in the urine within six to eight hours of administration. This renal elimination pathway has important implications for dosing in patients with impaired renal function, as the half-life of the medication increases as renal function declines. In patients with normal renal function, the half-life is approximately one to one and a half hours, but this can extend to five to twenty hours in patients with severe renal impairment. Dose adjustment based on the degree of renal dysfunction is essential to prevent drug accumulation and potential toxicity while maintaining therapeutic efficacy.
Standard adult dosing for most indications ranges from 250 mg to 500 mg three times daily, or 500 mg to 875 mg twice daily, depending on the severity of the infection and the susceptibility of the causative organism. The higher dosing regimens, such as 875 mg twice daily or 500 mg three times daily, are generally reserved for more serious infections or for infections caused by organisms with reduced susceptibility, such as penicillin-resistant Streptococcus pneumoniae. Pediatric dosing is based on body weight, with typical doses ranging from 20 to 45 mg per kilogram per day divided into two or three doses, with higher doses up to 90 mg per kilogram per day used for acute otitis media in settings where resistant pneumococci are prevalent.
The duration of therapy varies depending on the type and severity of the infection. Uncomplicated respiratory and urinary tract infections typically require five to seven days of treatment, while more serious or deep-seated infections may require ten to fourteen days or longer. Streptococcal pharyngitis should be treated for a full ten days regardless of the rate of symptomatic improvement, to ensure eradication of the organism and prevention of acute rheumatic fever. H. Pylori eradication regimens typically involve ten to fourteen days of combination therapy. Patients should be counseled that even if symptoms resolve before the completion of the prescribed course, the full course should be completed to minimize the risk of relapse and the development of antibiotic resistance.
Amoxicillin-clavulanate combinations
The combination of Amoxicillin with clavulanate potassium, known as co-amoxiclav, is an important therapeutic advance that extends the spectrum of activity of the medication to include beta-lactamase-producing organisms that would otherwise be resistant. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates many of the beta-lactamase enzymes produced by bacteria as a resistance mechanism. By protecting Amoxicillin from enzymatic degradation, clavulanate restores the activity of the antibiotic against organisms that have acquired resistance through beta-lactamase production, including many strains of Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Bacteroides species.
While Cepmox itself contains Amoxicillin alone without a beta-lactamase inhibitor, it is important for patients and prescribers to understand the distinction between these formulations and the circumstances in which each is appropriate. Amoxicillin alone is appropriate for infections caused by organisms known to be susceptible or for empiric therapy in settings where the prevalence of beta-lactamase-mediated resistance is low. The combination product is preferred when broader coverage is needed, such as in the treatment of human or animal bite wounds, diabetic foot infections, and certain respiratory tract infections in which beta-lactamase-producing organisms are likely to be present. The addition of clavulanate does, however, increase the incidence of gastrointestinal side effects, particularly diarrhea, which can be a limiting factor in treatment adherence.
Antibiotic resistance and stewardship
The emergence and spread of antibiotic resistance is one of the most significant public health challenges of the modern era, threatening to undermine the gains achieved through decades of antibiotic use. The mechanisms by which bacteria become resistant to Amoxicillin and other beta-lactam antibiotics are well characterized and include the production of beta-lactamases that hydrolyze the beta-lactam ring, alterations in penicillin-binding proteins that reduce the affinity of the antibiotic for its target, and decreased permeability of the bacterial outer membrane that limits antibiotic access to its site of action. The accumulation and dissemination of these resistance mechanisms have resulted in increasing rates of resistance among many clinically important pathogens, necessitating adjustments in empiric treatment recommendations and noting the importance of antibiotic stewardship.
Responsible use of Cepmox and all antibiotics is essential to preserve their effectiveness for future generations. Antibiotics should be prescribed only when there is a reasonable likelihood of bacterial infection, as they are ineffective against viral illnesses including the common cold, most sore throats, and acute bronchitis. When antibiotics are indicated, the narrowest spectrum agent that is likely to be effective should be selected, and the shortest effective duration of therapy should be used. Culture and susceptibility testing should be utilized whenever possible to guide targeted therapy and to de-escalate from empiric broad-spectrum coverage to narrow-spectrum treatment based on the identified organism.
Patients have an important role to play in antibiotic stewardship as well. The expectation that antibiotics will be prescribed for viral illnesses should be challenged through public education about the difference between bacterial and viral infections and the limitations of antibiotic therapy. When antibiotics are prescribed, patients should adhere to the dosing schedule, complete the full course of treatment, and never share antibiotics with others or use leftover antibiotics from a previous prescription. Unused antibiotics should be properly disposed of rather than saved for future use, as expired medications may be degraded and potentially harmful, and the casual use of antibiotics for unverified indications contributes to the resistance problem.
Learn more about Cepmox and antibiotic treatment at Happy Family Pharmacy
Side effect profile and allergic reactions
The safety profile of Cepmox is generally favorable, with most side effects being mild, transient, and gastrointestinal in nature. Diarrhea is the most common adverse effect, resulting from the disruption of the normal intestinal microbiota by the antibiotic. This effect is dose-related and more common with higher doses and longer durations of therapy. In most cases, the diarrhea is mild and self-limited, resolving spontaneously after the completion of treatment. Probiotic supplementation during and after antibiotic therapy may help reduce the incidence and severity of antibiotic-associated diarrhea by supporting the restoration of a healthy gut microbiome.
Nausea, vomiting, and abdominal discomfort can occur with Amoxicillin, although these symptoms are less common than diarrhea and may be minimized by taking the medication with food. In contrast to some other antibiotics, the absorption of Amoxicillin is not impaired by food intake, so taking the medication with meals is a reasonable strategy for reducing gastrointestinal intolerance. For patients who experience significant gastrointestinal side effects, alternative formulations or dosing schedules may be considered in consultation with the healthcare provider.
Hypersensitivity reactions to penicillins, including Amoxicillin, are among the most important adverse effects to recognize and manage. Allergic reactions can range from mild skin rashes to severe and potentially life-threatening anaphylaxis. The classic morbilliform rash that appears several days into a course of Amoxicillin, particularly in patients with viral infections such as Epstein-Barr virus, is often not a true allergic reaction and does not necessarily contraindicate future use of the medication, although this determination should be made by a healthcare professional. True IgE-mediated allergic reactions, which can present with urticaria, angioedema, bronchospasm, and anaphylaxis, are an absolute contraindication to further penicillin use. Patients with a history of penicillin allergy should be carefully evaluated, as many individuals who report penicillin allergy are not truly allergic, and appropriate testing can help clarify the situation and expand therapeutic options.
Drug interactions
Cepmox participates in several clinically significant drug interactions that prescribers and patients should be aware of. One of the most important interactions is with methotrexate, a medication used for the treatment of rheumatoid arthritis, psoriasis, and certain malignancies. Amoxicillin can reduce the renal clearance of methotrexate, leading to increased serum concentrations and an increased risk of methotrexate toxicity, which can manifest as bone marrow suppression, gastrointestinal mucositis, and hepatic and renal dysfunction. Patients taking methotrexate should generally avoid Amoxicillin when possible, and if concurrent use is necessary, close monitoring of methotrexate levels and clinical status is essential.
Oral anticoagulants, particularly warfarin, represent another important interaction risk. While Amoxicillin itself does not have a direct anticoagulant effect, the alteration of the gut microbiome by antibiotics can reduce the endogenous production of vitamin K by intestinal bacteria, potentially enhancing the anticoagulant effect of warfarin. Also, the infection being treated can itself affect the metabolism of anticoagulants and the coagulation system. Patients on warfarin who require Amoxicillin therapy should have their international normalized ratio monitored more frequently, and warfarin dose adjustments may be necessary during and immediately after the course of antibiotic therapy.
Oral contraceptives have long been the subject of concern regarding potential interactions with antibiotics, based on the theoretical possibility that antibiotic-induced alterations in gut flora could reduce the enterohepatic recirculation of estrogen and thereby reduce contraceptive efficacy. The evidence for a clinically significant interaction between Amoxicillin and oral contraceptives is limited, and most authorities do not recommend additional contraceptive precautions during short courses of Amoxicillin. However, given significant consequences of unintended pregnancy, some patients and clinicians may prefer to use additional barrier contraception during antibiotic therapy as a precautionary measure.
Allopurinol, a medication used for the treatment of gout and hyperuricemia, has been associated with an increased risk of skin rash when coadministered with Amoxicillin. The mechanism of this interaction is not well understood, but the combination is not contraindicated, and patients who develop a rash while taking both medications should be evaluated to determine the likely cause and the appropriate management strategy. Probenecid, another medication used for gout, competitively inhibits the renal tubular secretion of Amoxicillin, leading to increased and prolonged serum concentrations of the antibiotic. This interaction has been exploited therapeutically to achieve higher antibiotic levels in certain clinical situations, although it is not commonly used in routine practice.
Use in special populations
The use of Cepmox in pregnant women is generally considered safe, with the medication classified as pregnancy category B by the United States Food and Drug Administration based on animal studies that have not demonstrated fetal risk and the absence of adequate and well-controlled studies in pregnant women. Amoxicillin has been used in pregnancy for the treatment of urinary tract infections, respiratory infections, and other bacterial infections, without evidence of increased risk of congenital malformations or adverse pregnancy outcomes. The medication crosses the placenta and achieves therapeutic concentrations in fetal tissues, which can be beneficial in the treatment of intra-amniotic infection and raises the theoretical concern of potential fetal effects.
Breastfeeding women can generally use Amoxicillin safely, as the amount of medication excreted in breast milk is small and not expected to cause adverse effects in the nursing infant. The American Academy of Pediatrics considers Amoxicillin compatible with breastfeeding, although like all medications, it should be used during lactation only when clearly needed. Potential effects on the infant include alteration of the gastrointestinal flora, which could theoretically cause diarrhea or thrush, although clinically significant effects are uncommon at standard maternal doses.
Pediatric patients represent a population in whom Amoxicillin is particularly widely used, given high incidence of respiratory infections, otitis media, and streptococcal pharyngitis in this age group. The availability of liquid formulations of Amoxicillin, including suspensions in various concentrations and flavors, facilitates accurate weight-based dosing and improves palatability and adherence in children. Pediatric dosing calculators and weight-based dosing guides are essential tools to ensure that the correct dose is administered, as both underdosing and overdosing carry risks in this vulnerable population. Parents should be provided with clear instructions and appropriate measuring devices, and the importance of completing the full course of treatment should be emphasized.
Elderly patients may have age-related declines in renal function that necessitate dose adjustment of renally eliminated medications including Amoxicillin. The serum creatinine level alone may not be a reliable indicator of renal function in elderly patients, as the age-related decline in muscle mass can mask reductions in glomerular filtration rate. Calculation of creatinine clearance using formulas that incorporate age, weight, and serum creatinine is recommended for accurate assessment of renal function and appropriate dose adjustment. Elderly patients may also be at increased risk for certain adverse effects of antibiotic therapy, including Clostridium difficile infection, and should be monitored accordingly.
Clostridium difficile and microbiome considerations
One of the most significant potential adverse effects of antibiotic therapy, including treatment with Cepmox, is the development of Clostridium difficile infection. C. Difficile is an anaerobic, spore-forming bacterium that can overgrow in the colon when the normal gut microbiota is disrupted by antibiotic exposure. The organism produces toxins that damage the colonic mucosa, resulting in a spectrum of illness ranging from mild diarrhea to fulminant pseudomembranous colitis with toxic megacolon, sepsis, and death. The risk of C. Difficile infection is related to the spectrum and duration of antibiotic therapy, with broader-spectrum agents and longer courses associated with higher risk.
The diagnosis of C. Difficile infection should be considered in any patient who develops diarrhea during or within several weeks of antibiotic therapy. Diagnostic testing involves the detection of C. Difficile toxins in stool specimens, typically using enzyme immunoassay or nucleic acid amplification testing. If C. Difficile infection is confirmed, the inciting antibiotic should be discontinued if possible, and specific anti-C. Difficile therapy should be initiated. First-line treatment options include oral vancomycin or fidaxomicin, with metronidazole reserved for milder cases in settings where these agents are not available. Infection control measures, including contact precautions and environmental cleaning with sporicidal agents, are essential to prevent transmission to other patients.
The recognition of the importance of the gut microbiome to human health has led to increasing interest in strategies to preserve and restore the microbiome during and after antibiotic therapy. Probiotic preparations containing various strains of Lactobacillus, Bifidobacterium, and Saccharomyces have been studied for the prevention of antibiotic-associated diarrhea and C. Difficile infection, with some evidence of modest benefit. While probiotics are generally safe and may be considered as an adjunct to antibiotic therapy, they are not a substitute for appropriate antibiotic stewardship, and their use should be informed by the available evidence and individual patient factors.
Mechanisms of bacterial resistance
The continued effectiveness of Cepmox depends on understanding and mitigating the mechanisms by which bacteria develop resistance to beta-lactam antibiotics. The most common and clinically significant resistance mechanism is the production of beta-lactamase enzymes, which hydrolyze the beta-lactam ring and render the antibiotic inactive before it can reach its target penicillin-binding proteins. These enzymes are encoded by genes that can be located on the bacterial chromosome or on mobile genetic elements such as plasmids, which facilitate their horizontal transfer between bacteria of the same and different species. The widespread use of antibiotics has created selective pressure that favors the survival and proliferation of beta-lactamase-producing strains, leading to increasing rates of resistance among many clinically important pathogens.
Alteration of penicillin-binding proteins is another important resistance mechanism, most famously exemplified by methicillin-resistant Staphylococcus aureus, or MRSA. In these organisms, the acquisition of the mecA gene results in the production of an altered penicillin-binding protein, PBP2a, that has a very low affinity for beta-lactam antibiotics including Amoxicillin. The organism is therefore able to synthesize its cell wall normally even in the presence of the antibiotic, rendering treatment with beta-lactams ineffective. The spread of MRSA from healthcare settings into the community has complicated the empiric treatment of skin and soft tissue infections, as Amoxicillin and other beta-lactams are no longer reliable choices when staphylococcal infection is suspected.
Decreased permeability of the bacterial outer membrane, a resistance mechanism particularly relevant to gram-negative bacteria, reduces the ability of Amoxicillin to reach its target penicillin-binding proteins in the periplasmic space. In gram-negative organisms, the outer membrane is a permeability barrier that restricts the entry of many antibiotics, and alterations in porin proteins, the channels through which antibiotics enter the bacterial cell, can further reduce antibiotic access. This mechanism often coexists with beta-lactamase production, and the combination of reduced entry and enzymatic degradation can produce high-level resistance that is difficult to overcome with any concentration of antibiotic. The emergence and spread of multidrug-resistant gram-negative organisms, including extended-spectrum beta-lactamase-producing Enterobacteriaceae, is one of the most serious threats to the continued utility of Amoxicillin and other beta-lactam antibiotics.
Antibiotic stewardship in action
Antibiotic stewardship programs, now mandated in many healthcare facilities, provide a framework for optimizing antibiotic use to improve patient outcomes while minimizing the unintended consequences of antibiotic therapy including the development of resistance, adverse drug events, and Clostridium difficile infection. Key stewardship strategies applicable to the use of Cepmox include the restriction of empiric use to situations in which bacterial infection is likely based on clinical presentation, the use of the narrowest spectrum agent that is likely to be effective, the selection of the shortest effective duration of therapy, and the de-escalation of therapy based on culture and susceptibility results when available. These strategies are not intended to deny antibiotics to patients who need them but rather to ensure that antibiotics are used in an evidence-based manner that maximizes benefit and minimizes harm at both the individual and population levels.
Diagnostic stewardship is an important complement to antibiotic stewardship, as the appropriate use of antibiotics depends on the accurate diagnosis of bacterial infection. Rapid diagnostic tests, including point-of-care tests for group A streptococcus in pharyngitis and biomarkers such as procalcitonin that can help distinguish bacterial from viral infections, can support more targeted antibiotic prescribing. The implementation of clinical decision support tools, including electronic health record alerts and order sets that guide prescribers toward guideline-concordant antibiotic choices, can reduce the variability in prescribing and improve the quality of antibiotic use. Education of both prescribers and patients about the appropriate use of antibiotics is a foundational element of stewardship that should begin in medical training and continue throughout clinical practice.
Patient education is a critical component of antibiotic stewardship, as patient expectations and demands are a significant driver of unnecessary antibiotic prescribing. Patients who understand that antibiotics are ineffective against viral infections and that the natural history of most acute respiratory illnesses is one of spontaneous resolution are less likely to request antibiotics and more likely to be satisfied with a management plan that emphasizes symptom relief and watchful waiting. The communication strategy of providing a positive recommendation for symptomatic treatment while offering a contingency plan for follow-up if symptoms do not improve as expected, known as delayed prescribing, has been shown to reduce antibiotic use without decreasing patient satisfaction. Healthcare providers should be trained in these communication strategies and should be supported in their efforts to provide evidence-based care that may sometimes require saying no to patient requests for antibiotics.
Microbiological diagnosis and culture-guided therapy
When the clinical situation permits, the identification of the causative organism and its antibiotic susceptibility profile through microbiological testing can guide the targeted use of Cepmox and help ensure that the antibiotic selected is the most appropriate for the specific infection being treated. Specimens for culture should be obtained before antibiotics are administered whenever possible, as prior antibiotic exposure can suppress the growth of organisms in culture and lead to false-negative results. The selection of the appropriate specimen type based on the suspected site of infection, the proper collection technique to avoid contamination, and the prompt transport of specimens to the laboratory are essential for maximizing the yield and clinical utility of microbiological testing.
The interpretation of culture results requires an understanding of the distinction between colonization and infection, as the mere presence of bacteria in a culture does not necessarily indicate that those bacteria are causing disease. Many body sites, including the skin, upper respiratory tract, and gastrointestinal tract, normally harbor a diverse microbiota that includes organisms that can be pathogenic under certain circumstances but are harmless commensals in their usual context. The clinical significance of a positive culture must be assessed in light of the patient’s clinical presentation, the site from which the specimen was obtained, the quantity of organisms recovered, and the specific organisms identified. The isolation of organisms that are uncommon causes of infection at the sampled site or that are present in low numbers may represent colonization or contamination rather than true infection.
Antibiotic susceptibility testing provides information about which antibiotics are likely to be effective against the isolated organism, guiding the selection of targeted therapy that is both effective and as narrow-spectrum as possible. Susceptibility testing is typically performed using standardized methods that determine the minimum inhibitory concentration, or MIC, of each antibiotic against the organism. The MIC is compared to established breakpoints to categorize the organism as susceptible, intermediate, or resistant to each antibiotic. For infections in which Amoxicillin is a therapeutic option, susceptibility testing can confirm that the organism is likely to respond to treatment, providing confidence in the antibiotic choice and avoiding the use of unnecessarily broad-spectrum alternatives. When susceptibility testing indicates resistance to Amoxicillin, alternative antibiotics should be selected based on the susceptibility profile and the clinical characteristics of the infection.